Y-box binding protein-1 (YBX1), a multifunctional oncoprotein containing an evolutionarily conserved cold shock domain, dysregulates a wide range of genes involved in cell proliferation and survival, drug resistance, and chromatin destabilization by This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| Y-BOXB IND INGPROTEIN -TR ANSCRIP TIONALLYAC TIVATE SABC TR AN S P ORTERG ENECONFERRING C AN CER-ACQUIREDMULTIDRUG RE S IS TAN CE
One of the most significant obstacles to anticancer therapy is the emergence of drug-resistant tumors. Development of potent therapeutic drugs that can overcome drug resistance is a persistent challenge for cancer researchers. Over the past five decades, the classical approach of selecting drug-resistant cancer cells through chronic exposure of drug-sensitive cancer cells to anticancer agents has been used to elucidate how cells acquire drug resistance, in addition to how drug resistance-reversal therapies are developed. 1, 2 One representative ABC transporter gene, ABCB1, encodes a membrane glycoprotein catalyzing the ATP-dependent efflux of multiple anticancer agents, and the efflux activity is closely associated with the acquisition of the most classical multidrug resistance ( Figure 1A ). 3, 4 In one example, the same drug-sensitive parental cell line was used to select two multidrug-resistant cell lines; KB-C1 5 was selected as colchicine-resistant cells and KB/VJ300 6 was selected as vincristineresistant cells. ABCB1 is amplified in resistant KB-C1 cells, 7 and the amplified region spans approximately 1-2 Mb on the human chromosome 7q21.12. 8 In contrast, overexpression of the ABCB1 protein was also observed in resistant KB/VJ300 cells without gene amplification. 6 Therefore, ABCB1 is overexpressed through either gene amplification or transcriptional activation. Among 51 ABC transporters, ABCB1 is one of the major transporters of clinical significance. 9 As a major mechanism of ABCB1 overexpression, transcriptional activation of ABCB1 is most often reported in various human malignancies and in cancer cell lines ( Figure 1A ). Y-box binding protein-1 (YBX1) binds to the Y-box sequence in the 5′-flanking region of ABCB1 in drug-resistant cancer cells to promote its transcriptional activation ( Figure 1A ,B). [10] [11] [12] [13] In addition, YBX1
binds to the Y-box sequence in many other drug resistance-related genes ( Figure 1B) . 11, [14] [15] [16] [17] [18] [19] [20] Therefore, YBX1 drives the acquisition of drug resistance in cancer cells through its transcriptional activation. [21] [22] [23] YBX1 is a member of the cold shock domain protein superfamily, which is considered the most evolutionarily conserved nucleic acidbinding protein from bacteria to human ( Figure 1C ). 21, 24 YBX1 was initially identified as a transcription factor that binds to the Y-box sequence of the 5′-flanking region of the ovalbumin gene, 25 the major histocompatibility complex class gene, 26 and of epidermal growth factor receptor (EGFR). 27 The consensus sequence binding site for YBX1
is 5′-CTGATTGG-3′, namely, the inverted CCAAT box ( Figure 1B ).
YBX1 is localized in both the cytoplasm and nucleus of cancer cells (Figure 2A ). YBX1 translocates from the cytoplasm to the nucleus when F I G U R E 1 A, Among 51 ABC transporters, ABCB1 is a representative transporter that enhances outward efflux activity of anticancer drugs from the inside to the outside of cancer cells, resulting in acquired multidrug resistance. Enhanced transcriptional activation of ABCB1, either by chronic exposure to anticancer drugs or by acquired multidrug resistance, is mediated through the environmental stimulinaïve Y-box binding protein-1 (YBX1). B, YBX1-induced activation of ABCB1 is first presented as a transcriptional mechanism of how tumor multidrug resistance is acquired during chemotherapeutic treatments in various human malignancies. YBX1 also induces activation of various other resistance-related genes, including MVP/LRP, TOP2A, CD44, CD49f, BCL2, MYC, and androgen receptor (AR). C, Structure and phosphorylation sites of the YBX1 protein. Phosphorylation at Ser102 in the cold shock domain is essential for nuclear translocation and oncogenic activation of YBX1. B/A repeat, basic and acidic amino acid repeat sequences exposed to various environmental stimuli in vitro and in vivo, 11, 12, 28, 29 as well as in cancer cells in patients treated with anticancer therapeutic drugs. 30 YBX1 in the nucleus plays a major role as a transcription factor for various drug resistance-related genes, including ABCB1, and in the repair of damaged DNA. However, in the cytoplasm, YBX1 is mainly involved in post-transcriptional control of several mRNA splices, including epithelial-to-mesenchymal transition-related genes. 31, 32 In the present review, we focus on the oncogenic role of YBX1, its localization in the nucleus, and its association with drug resistance.
| Y-BOXB IND INGPROTEIN -1 DYS REG UL ATE SG ENE SINVOLVEDIN DRUGRE S IS TAN CEANDTUMORG ROW TH PROMOTION
Immunohistochemistry (IHC) analyses have mainly been used to investigate whether nuclear and/or cytoplasmic expression of YBX1 is enhanced in cancer. 28 
| ENHAN CEDYBX1E XPRE SS I ON PRED I C TSP OOROUTCOME SINVARI OUS HUMANMALIG NAN CIE S
Kamura et al 34 Similarly, carcinogenesis and further malignant progression of cancer are associated with the nine hallmarks of cancer, including cell proliferation, survival, immortalization, inflammation, invasion, metastasis, and others. 35 In addition, most of the hallmarks are closely coupled with enhanced expression of YBX1. 32 
| Y-BOXB IND INGPROTEIN -1 ISANEFFEC TIVEP OTENTTARG E T INOVERCOMINGANTI -E S TROG EN RE S IS TAN CEBYB RE A S TC AN CER
Among the numerous human tumor types, the clinical significance of YBX1 has been most extensively studied in breast cancer ( Figure 3A) and acquired resistance to tamoxifen, a representative anti-estrogen, in therapeutic experimental models in vivo ( Figure 3B ). Figure 3D,E) . 37, 51 In the present study, 352 of the top 500 genes were shown to be both positively correlated with ESR1 and negatively correlated with YBX1
( Figure 3E) . 37, 51 Therefore, the enhanced expression of YBX1 is reciprocally associated with reduced expression of various ERα-targeted genes, indicating that YBX1 preferentially promotes ERα-independent tumor growth and survival. The findings suggest that YBX1 has oncogenic potential in breast cancer and that YBX1 could be a therapeutic target in breast cancer refractory to endocrine therapeutics.
| PHOS PHORYL ATIONANDNUCLE AR LO C ALIZ ATI ONOFYBX1AREREQU IRED FORITSON COG ENI CDRIVERFUN C TI ON S
Nuclear localization of YBX1 predicts poor outcomes in patients with various cancers (Table 1 at Ser102 is essential for its nuclear translocation in cancer cells. YBX1 Ser102 phosphorylation is suppressed by inhibitors of PI3K, mTORC1, and p90 ribosomal S6 kinase (RSK). 29, [52] [53] [54] Figure 4B shows the suppression of nuclear localization by a PI3K inhibitor (LY294002) or an mTORC1 inhibitor (everolimus). Consistent with Figure 4B , an Ser102 phosphorylation-null mutant construct of YBX1 could not be translocated into the nucleus, which was accompanied by downregulated expression of EGFR and HER2, in breast cancer cells. 52 Therefore, various kinases involved in AKT/mTOR and MEK/ERK signaling pathways influence both the phosphorylation and nuclear translocation of YBX1 ( Figure 4C ).
| TARG E TINGYBX1CONTRIBUTE STO FURTHERDE VELOPMENTOFEFFEC TIVE ANTI C AN CERTHER APEUTI C S
Preclinical therapeutic studies targeting YBX1 itself have been assessed. A molecular decoy cell permeable peptide of nine amino acids that flank the YBX1 Ser102 site induced cytotoxicity in cancer cells in vitro. 55 Other preclinical therapeutic approaches involving the silencing of YBX1 with siRNAs or miRNAs have been carried out.
A Dectin-1-targeting vehicle delivering YBX1 antisense DNA has been developed by making use of a novel polysaccharide drug delivery system, and the YBX1 silencing approach showed some suppression effects on cell viability in vitro. 56 Another study has reported that silencing of YBX1 expression using long noncoding RNA induces cell growth suppression in lung cancer cells. 57 
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